H1 2022 marked by the start of recruitment for the phase 2b study with AEF0117 for the treatment of cannabis addiction Solid cash position at €39.8 million as of June 30, 2022, including the
Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today
Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the Company »),
BORDEAUX, France (BUSINESS WIRE) Regulatory News:Aelis Farma (ISIN code: FR0014007ZB4 – ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the « Company »), informs its shareholders and the financial community that the Company’s Ordinary Gene.
AEF0117 is the most advanced drug candidate of the new pharmacological class, the CB1-SSi, developed by Aelis Farma. AEF0117 aims to treat disorders related to excessive cannabis use (addiction